Innovate, Involve, Inspire
- Sponsor
- Frontline AIDS
- Study ID
- NCT06604182
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 60 Years
- Healthy Volunteers
- Accepted
Interventions
- Community-based Simplified HCV Testing and Treatment Algorithm — OTHERThe distinctive features of CBSA are: (i) community-based service provision, substantially lowering the threshold for HCV services and eliminating the need to visit health care facilities for the majority of patients; (ii) the use of simple, once-daily, pan-genotypic HCV treatment regimens; (iii) a minimum of required laboratory tests and assessments; (iv) task sharing of essential functions from physicians to the case-managers; (v) integration of HCV testing and treatment with existing harm reduction services, addressing multiple health needs and facilitating patient-centered care.
Study Details
The study will test a Community-based Simplified HCV Testing and Treatment Algorithm (CBSA), implemented at community harm reduction fixed or mobile sites. All potential participants with positive anti-HCV test will undergo diagnostic procedures including HCV-RNA testing. Those eligible for CBSA will be prescribed a fixed dose combination tablet: sofosbuvir/daclatasvir. Sustained virologic response (SVR) will be assessed 12 weeks after treatment completion. All those who achieve SVR will be tested for HCV\_RNA at six and 12 months after SVR12.
Key Dates
- Start date
- Jan 31, 2025
- Status verified
- Sep 2024
- Primary completion
- Jun 30, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 1,454 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: HCV positiveEligible participants that are HCV infected.
Primary Outcome Measure
Number of participants successfully completing HCV treatment [ Time Frame: 15 months ]
Central Contacts
- Anna Meteliuk, PhD+380988220510
- Abraham J Olivier, PhD+447775912022
Related Studies
- Appalachian Partnership to Reduce Disparities (Aim 2)Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- A Setting Focus Overdose Prevention InterventionRecruiting · Johns Hopkins Bloomberg School of Public Health · Baltimore, Maryland
- Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected RecipientsRecruiting · Johns Hopkins University · La Jolla, California
- HIV/HBV/HCV Triple Screening in Primary CareNot Yet Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas